enoyl-acyl carrier protein reductase (fabi)

Vinaxanthone (SM-345431) is a small molecule compound derived from Penicillium chrysogenum that acts as a selective and potent inhibitor of semaphorin3A, phospholipase C (PLC), and FabI, exhibiting antimicrobial activity by blocking intracellular fatty acid synthesis and inhibiting the growth of Staphylococcus aureus.

Nilofabicin (CG-400549) is a potent inhibitor of enoyl-(acyl-carrier-protein) reductase fall(FabI) and can be used in studies about the treatment of complicated acute.

Debio-1452-NH3 is a novel and potent FabI antibody—enoyl-acyl carrier protein reductase inhibitor that demonstrates excellent efficacy in reducing bacterial load in mice. It effectively treats lethal infections caused by clinically isolated strains of Pseudomonas aeruginosa (Acinetobacter baumannii), Klebsiella pneumoniae, and Escherichia coli (E. coli).

AFN-1252 (Debio 1452)(Debio 1452) is an effective inhibitor of enoyl-acyl carrier protein reductase (FabI). It (≤0.12 μg/ml) inhibits all Clinicalal isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Afabicin (formerly Debio 1450, AFN-1720) is a prodrug of afabicin desphosphono, an enoyl-acyl carrier protein reductase (FabI) inhibitor, and is a first-in-class antibiotic with a novel mode of action to specifically target fatty acid synthesis in Staphylococcus spp.